In the Claims:

1-15. (Canceled)

16. (Previously Presented) A compound of formula (I)



(I)

wherein

---- represents a single or a double bond;

R is a radical selected from:



i) ii) iii) and iv)

in which $R_1$ is halogen, cyano, $C_{1-4}$ alkyl, $C_{1-4}$ alkoxy, trifluoromethyl or trifluoromethoxy and p is zero or an integer from 1 to 3;

$R_2$ is hydrogen or $C_{1-4}$ alkyl;

$R_3$ is hydrogen, hydroxy or $C_{1-4}$ alkyl;

$R_4$ is hydrogen or $R_4$ together with $R_3$ is =O or $=CH_2$;

$R_5$ is phenyl, naphthyl, a 9 to 10 membered fused bicyclic heterocyclic group or a 5 or 6 membered heteroaryl group, wherein said groups are optionally substituted by 1 to 3 groups independently selected from trifluoromethyl, $C_{1-4}$ alkyl, hydroxy, cyano, $C_{1-4}$ alkoxy, trifluoromethoxy, halogen or $S(O)_qC_{1-4}$ alkyl;

$R_6$ and $R_7$ independently are hydrogen, cyano, $C_{1-4}$ alkyl;

$R_8$ is $(CH_2)_rR_{10}$;

$R_9$ is hydrogen, halogen, $C_{3-7}$ cycloalkyl, hydroxy, nitro, cyano or $C_{1-4}$ alkyl optionally substituted by one or two groups selected from halogen, cyano, hydroxy or $C_{1-4}$ alkoxy;

$R_{10}$ is hydrogen or $C_{3-7}$ cycloalkyl;

n is 2;

q is 0, 1 or 2;

r is 0 or an integer from 1 to 4;

or a pharmaceutically acceptable salt thereof.

17. (Canceled).

18. (Previously Presented) A compound as claimed in claim 1 wherein R is:



wherein $R_1$ is halogen, $C_{1-4}$ alkyl, cyano, $C_{1-4}$ alkoxy, trifluoromethyl or trifluoromethoxy and p is zero or an integer from 1 to 3.

19. (Previously Presented) A compound as claimed in claim 1 wherein $R_5$ is phenyl or naphthyl optionally substituted by one or two groups selected from trifluoromethyl, cyano, $C_{1-4}$ alkyl or halogen.

20. (Previously Presented) A compound as claimed claim 1 wherein $R_8$ is $(CH_2)_rR_{10}$ wherein $R_{10}$ is hydrogen or $C_{3-7}$ cycloalkyl and r is 0 or 1.

21. (Previously Presented) A compound as claimed in claim 1, wherein $R_9$ is hydrogen or $C_{1-4}$ alkyl optionally substituted by one or two halogens.

22. (Previously Presented) A compound as claimed in claim 1 wherein:

R is phenyl substituted by a fluorine;

$R_2$, $R_9$ and $R_4$ are each hydrogen;

$R_3$ is hydrogen, hydroxy or methyl, or $R_3$ together with $R_4$ is =O or $=CH_2$;

$R_6$ and $R_7$ are independently hydrogen or methyl;

$R_5$ is phenyl or naphthyl optionally substituted by one or two groups independently selected from cyano, methyl, chlorine, bromine or fluorine atom; and

$R_8$ is hydrogen, methyl or cyclopropylmethyl.

23. (Previously Presented) A compound selected from:

1-[(3,5-Dichlorophenyl)methyl]-3-[4-(4-fluorophenyl)-4-piperidinyl]-1,5-dihydro-2*H*-pyrrol-2-one;

1-[(3,5-Dichlorophenyl)methyl]-3-[4-(4-fluorophenyl)-1-methyl-4-piperidinyl]-1,5-dihydro-2*H*-pyrrol-2-one ;

1-[1-(3,5-Dichlorophenyl)ethyl]-3-[4-(4-fluorophenyl)-4-piperidinyl]-1,5-dihydro-2*H*-pyrrol-2-one (Chain Enantiomer 1);

1-[(1*S*)-1-(3-Chloro-1-naphthalenyl)ethyl]-3-[4-(4-fluorophenyl)-4-piperidinyl]-1,5-dihydro-2*H*-pyrrol-2-one ;

1-[(3-Chloro-1-naphthalenyl)methyl]-3-[4-(4-fluorophenyl)-4-piperidinyl]-1,5-dihydro-2*H*-pyrrol-2-one;

4-({3-[4-(4-Fluorophenyl)-4-piperidinyl]-2-oxo-2,5-dihydro-1*H*-pyrrol-1-yl}methyl)-2-naphthalenecarbonitrile;

1-[1-(3,5-Dichlorophenyl)ethyl]-3-[4-(4-fluorophenyl)-4-piperidinyl]-1,5-dihydro-2*H*-pyrrol-2-one (Chain Enantiomer 2);

1-[(1*R*)-1-(3-Chloro-1-naphthalenyl)ethyl]-3-[4-(4-fluorophenyl)-4-piperidinyl]-1,5-dihydro-2*H*-pyrrol-2-one;

1-[1-(3,5-Dichlorophenyl)ethyl]-3-[4-(4-fluorophenyl)-1-methyl-4-piperidinyl]-1,5-dihydro-2*H*-pyrrol-2-one (Chain Enantiomer 1);

1-[(1*S*)-1-(3-Chloro-1-naphthalenyl)ethyl]-3-[4-(4-fluorophenyl)-1-methyl-4-piperidinyl]-1,5-dihydro-2*H*-pyrrol-2-one ;

1-[(3-Chloro-1-naphthalenyl)methyl]-3-[4-(4-fluorophenyl)-1-methyl-4-piperidinyl]-1,5-dihydro-2*H*-pyrrol-2-one;

1-[1-(3,5-Dichlorophenyl)ethyl]-3-[4-(4-fluorophenyl)-1-methyl-4-piperidinyl]-1,5-dihydro-2*H*-pyrrol-2-one (Chain Enantiomer 2);

1-[(1*R*)-1-(3-Chloro-1-naphthalenyl)ethyl]-3-[4-(4-fluorophenyl)-1-methyl-4-piperidinyl]-1,5-dihydro-2*H*-pyrrol-2-one;

4-({3-[4-(4-Fluorophenyl)-1-methyl-4-piperidinyl]-2-oxo-2,5-dihydro-1*H*-pyrrol-1-yl}methyl)-2-naphthalenecarbonitrile;

1-[1-(3,5-Dichlorophenyl)ethyl]-3-[4-(4-fluorophenyl)-1-methyl-4-piperidinyl]-1,5-dihydro-2*H*-pyrrol-2-one hydrochloride (Chain Enantiomer 1);

1-[1-(3,5-Dichlorophenyl)ethyl]-3-[4-(4-fluorophenyl)-1-methyl-4-piperidinyl]-1,5-dihydro-2*H*-pyrrol-2-one hydrochloride (Chain Enantiomer 1);

1-[(3-Chloro-1-naphthalenyl)methyl]-3-[1-(cyclopropylmethyl)-4-(4-fluorophenyl)-4-piperidinyl]-1,5-dihydro-2*H*-pyrrol-2-one;

1-[(3,5-Dichlorophenyl)methyl]-3-[4-(4-fluorophenyl)-4-piperidinyl]-2-pyrrolidinone

1-[(1*S*)-1-(3-Chloro-1-naphthalenyl)ethyl]-3-[4-(4-fluorophenyl)-4-piperidinyl]-2-pyrrolidinone (Diastereoisomer 1);

1-[(1*S*)-1-(3-Chloro-1-naphthalenyl)ethyl]-3-[4-(4-fluorophenyl)-4-piperidinyl]-2-pyrrolidinone;

1-[1-(3,5-Dichlorophenyl)ethyl]-3-[4-(4-fluorophenyl)-4-piperidinyl]-2-pyrrolidinone (Diastereoisomer 1 Chain Enantiomer 1);

1-[1-(3,5-Dichlorophenyl)ethyl]-3-[4-(4-fluorophenyl)-4-piperidinyl]-2-pyrrolidinone (Diastereoisomer 2 Chain Enantiomer 1);

1-[1-(3,5-Dichlorophenyl)ethyl]-3-[4-(4-fluorophenyl)-4-piperidinyl]-2-pyrrolidinone (Diastereoisomer 1 Chain Enantiomer 2);

1-[1-(3,5-Dichlorophenyl)ethyl]-3-[4-(4-fluorophenyl)-4-piperidinyl]-2-pyrrolidinone (Diastereoisomer 2 Chain Enantiomer 2);

4-({3-[4-(4-Fluorophenyl)-4-piperidinyl]-2-oxo-1-pyrrolidinyl}methyl)-2-naphthalenecarbonitrile (Enantiomer 1);

4-({3-[4-(4-Fluorophenyl)-4-piperidinyl]-2-oxo-1-pyrrolidinyl}methyl)-2-naphthalenecarbonitrile (Enantiomer 2);

7-Fluoro-4-({3-[4-(4-fluorophenyl)-4-piperidinyl]-2-oxo-1-pyrrolidinyl}methyl)-2-naphthalenecarbonitrile (Enantiomer 2);

6-Fluoro-4-({3-[4-(4-fluorophenyl)-4-piperidinyl]-2-oxo-1-pyrrolidinyl}methyl)-2-naphthalenecarbonitrile (Enantiomer 2);

7-Fluoro-4-({3-[4-(4-fluorophenyl)-4-piperidinyl]-2-oxo-1-pyrrolidinyl}methyl)-2-naphthalenecarbonitrile (Enantiomer 1);

6-Fluoro-4-({3-[4-(4-fluorophenyl)-4-piperidinyl]-2-oxo-1-pyrrolidinyl}methyl)-2-naphthalenecarbonitrile (Enantiomer 1);

1-[(3,5-Dichlorophenyl)methyl]-3-[4-(4-fluorophenyl)-1-methyl-4-piperidinyl]-2-pyrrolidinone;

1-[1-(3-Chloro-1-naphthalenyl)ethyl]-3-[4-(4-fluorophenyl)-1-methyl-4-piperidinyl]-2-pyrrolidinone (Diastereoisomer 2 Chain Enantiomer 1);

1-[1-(3,5-Dichlorophenyl)ethyl]-3-[4-(4-fluorophenyl)-1-methyl-4-piperidinyl]-2-pyrrolidinone (Diastereoisomer 1 Chain Enantiomer 1);

1-[1-(3,5-Dichlorophenyl)ethyl]-3-[4-(4-fluorophenyl)-1-methyl-4-piperidinyl]-2-pyrrolidinone (Diastereoisomer 2 Chain Enantiomer 1);

1-[1-(3,5-Dichlorophenyl)ethyl]-3-[4-(4-fluorophenyl)-1-methyl-4-piperidinyl]-2-pyrrolidinone (Diastereoisomer 1 Chain Enantiomer 2);

1-[1-(3,5-Dichlorophenyl)ethyl]-3-[4-(4-fluorophenyl)-1-methyl-4-piperidinyl]-2-pyrrolidinone (Diastereoisomer 2 Chain Enantiomer 2);

1-[(3,5-Dichlorophenyl)methyl]-3-[4-(4-fluorophenyl)-1-methyl-4-piperidinyl]-2-pyrrolidinone (Enantiomer 1);

1-[(3,5-Dichlorophenyl)methyl]-3-[4-(4-fluorophenyl)-1-methyl-4-piperidinyl]-2-pyrrolidinone (Enantiomer 2);

4-({3-[4-(4-Fluorophenyl)-1-methyl-4-piperidinyl]-2-oxo-1-pyrrolidinyl}methyl)-2-naphthalenecarbonitrile (Enantiomer 1);

4-({3-[4-(4-Fluorophenyl)-1-methyl-4-piperidinyl]-2-oxo-1-pyrrolidinyl}methyl)-2-naphthalenecarbonitrile (Enantiomer 2);

7-Fluoro-4-({3-[4-(4-fluorophenyl)-1-methyl-4-piperidinyl]-2-oxo-1-pyrrolidinyl}methyl)-2-naphthalenecarbonitrile (Enantiomer 2);

6-Fluoro-4-({3-[4-(4-fluorophenyl)-1-methyl-4-piperidinyl]-2-oxo-1-pyrrolidinyl}methyl)-2-naphthalenecarbonitrile;

7-Fluoro-4-({3-[4-(4-fluorophenyl)-1-methyl-4-piperidinyl]-2-oxo-1-pyrrolidinyl}methyl)-2-naphthalenecarbonitrile (Enantiomer 1);

6-Fluoro-4-({3-[4-(4-fluorophenyl)-1-methyl-4-piperidinyl]-2-oxo-1-pyrrolidinyl}methyl)-2-naphthalenecarbonitrile (Enantiomer 1);

1-[(3,5-Dichlorophenyl)methyl]-3-[4-(4-fluorophenyl)-1-methyl-4-piperidinyl]-1*H*-pyrrole-2,5-dione;

1-[(3,5-Dichlorophenyl)methyl]-3-[4-(4-fluorophenyl)-1-methyl-4-piperidinyl]-5-methylidene-1,5-dihydro-2*H*-pyrrol-2-one;

and phamaceutically acceptable salts thereof.

24. (Previously Presented) A compound according to claim 23 in amorphous or crystalline form.

25. (Previously Presented) A compound selected from:

1-[(3,5-Dichlorophenyl)methyl]-3-[4-(4-fluorophenyl)-1-methyl-4-piperidinyl]-1,5-dihydro-2*H*-pyrrol-2-one;

1-[(3,5-Dichlorophenyl)methyl]-3-[4-(4-fluorophenyl)-1-methyl-4-piperidinyl]-1,5-dihydro-2*H*-pyrrol-2-one hydrochloride;

1-[(3,5-Dichlorophenyl)methyl]-3-[4-(4-fluorophenyl)-1-methyl-4-piperidinyl]-1,5-dihydro-2*H*-pyrrol-2-one fumarate;

1-[(3,5-Dichlorophenyl)methyl]-3-[4-(4-fluorophenyl)-1-methyl-4-piperidinyl]-1,5-dihydro-2*H*-pyrrol-2-one citrate.

26. (Previously Presented) A compound according to claim 25 in crystalline form.

27. (Previously Presented) 1-[(3,5-Dichlorophenyl)methyl]-3-[4-(4-fluorophenyl)-1-methyl-4-piperidinyl]-1,5-dihydro-2*H*-pyrrol-2-one citrate.

28. (Previously Presented) 1-[(3,5-Dichlorophenyl)methyl]-3-[4-(4-fluorophenyl)-4-piperidinyl]-1,5-dihydro-2*H*-pyrrol-2-one.

29. (Previously Presented) A pharmaceutical composition comprising a compound as claimed in claim 1 in admixture with one or more pharmaceutically acceptable carriers or excipients.

30. (Previously Presented) A pharmaceutical composition comprising a compound as claimed in claim 25 in admixture with one or more pharmaceutically acceptable carriers or excipients.

31. (Previously Presented) A pharmaceutical composition comprising a compound as claimed in claim 28 in admixture with one or more pharmaceutically acceptable carriers or excipients.

32. - 37. (Canceled).

38. – 44. (Canceled).